AUTHOR=Yang Kangping , Zhang Yihan , Ding Jiatong , Li Zelin , Zhang Hejin , Zou Fang 

TITLE=Autoimmune CD8+ T cells in type 1 diabetes: from single-cell RNA sequencing to T-cell receptor redirection

JOURNAL=Frontiers in Endocrinology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1377322

DOI=10.3389/fendo.2024.1377322

ISSN=1664-2392

ABSTRACT=Type 1 diabetes (T1D) is an organ-specific autoimmune disease caused by pancreatic β cell destruction and mediated primarily by autoreactive CD8+ T cells. It has been shown that only a small number of stem cell-like β cell-specific CD8+ T cells are needed to convert normal mice into T1D mice; thus, it is likely that T1D can be cured or significantly improved by modulating or altering selfreactive CD8+ T cells. However, stem cell-type, effector and exhausted CD8+ T cells play intricate and important roles in T1D. The highly diverse T-cell receptors (TCRs) also make precise and stable targeted therapy more difficult. Therefore, this review will investigate the mechanisms of autoimmune CD8+ T cells and TCRs in T1D, as well as the related single-cell RNA sequencing (ScRNA-Seq), CRISPR/Cas9, chimeric antigen receptor T-cell (CAR-T) and T-cell receptor-gene engineered T cells (TCR-T), for a detailed and clear overview. This review highlights that targeting CD8+ T cells and their TCRs may be a potential strategy for predicting or treating T1D.At present, there are many still unclear aspects of β cell-specific CD8+ T cells in T1D, such as the heterogeneity of CD8+ T cells (Kasmani et al., 2022) and the process of T-cell differentiation (Chá vez and Tse, 2021). still remain to be explored. These unclear issues affect the depth of related research; therefore, this paper will provide a detailed and clear review of the mechanism of autoimmune CD8+ T cells and TCR in T1D, as well as the important applications of scRNA-seq, CRISPR/Cas9, CAR-T and TCR-T.